About this FactMed analysis covering adverse side effect reports of PEG-INTRON patients who developed ACANTHOLYSIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking PEG-INTRON reported ACANTHOLYSIS to the FDA. A total of 13013 PEG-INTRON drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between PEG-INTRON and ACANTHOLYSIS. In doing so, we compare PEG-INTRON with other drugs that cause ACANTHOLYSIS, to help you evaluate whether or not PEG-INTRON causes ACANTHOLYSIS. Likewise, this page shows the most highly-reported side effects of PEG-INTRON, so you can see if ACANTHOLYSIS ranks among PEG-INTRON's most well-known side effects.
Summary Statistics
Reports of PEG-INTRON causing ACANTHOLYSIS: 1
Reports of any side effect of PEG-INTRON : 13013
Percentage of PEG-INTRON patients where ACANTHOLYSIS is a reported side effect: 0.0077%

FDA reports of any drug causing ACANTHOLYSIS : 33
Average percentage for all medicated patients where ACANTHOLYSIS is reported as a complication: 0.0002%

Physician opinion on PEG-INTRON as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing PEG-INTRON:
HEPATITIS C ( 9732 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 252 patients )
DRUG USE FOR UNKNOWN INDICATION ( 229 patients )
HEPATITIS ( 104 patients )
HEPATITIS B ( 98 patients )
MALIGNANT MELANOMA ( 76 patients )
CHRONIC HEPATITIS ( 43 patients )
METASTATIC MALIGNANT MELANOMA ( 34 patients )
HEPATIC CIRRHOSIS ( 33 patients )
HEREDITARY HAEMORRHAGIC TELANGIECTASIA ( 29 patients )
HEPATITIS C VIRUS ( 22 patients )
BONE SARCOMA ( 20 patients )
DRUG EXPOSURE DURING PREGNANCY ( 16 patients )
HEPATITIS C VIRUS TEST ( 14 patients )
MULTIPLE MYELOMA ( 13 patients )
POLYCYTHAEMIA VERA ( 7 patients )
CHRONIC MYELOID LEUKAEMIA ( 7 patients )
NON-HODGKIN'S LYMPHOMA ( 6 patients )
HEPATITIS VIRAL ( 6 patients )
HEPATITIS D ( 6 patients )
RENAL CELL CARCINOMA STAGE UNSPECIFIED ( 6 patients )
CHRONIC LEUKAEMIA ( 5 patients )
DISEASE RECURRENCE ( 4 patients )
METASTATIC RENAL CELL CARCINOMA ( 4 patients )
CARCINOID TUMOUR ( 4 patients )
ANTIVIRAL PROPHYLAXIS ( 3 patients )
ATRIAL FIBRILLATION ( 3 patients )
PREGNANCY ( 3 patients )
HIV INFECTION ( 3 patients )
LEUKAEMIA ( 3 patients )
NEUROFIBROMATOSIS ( 3 patients )
PLASMACYTOMA ( 3 patients )
HAIRY CELL LEUKAEMIA ( 3 patients )
ILL-DEFINED DISORDER ( 3 patients )
RENAL CANCER METASTATIC ( 3 patients )
HEPATIC NEOPLASM MALIGNANT ( 3 patients )
MYELOFIBROSIS ( 3 patients )
CARDIAC FAILURE CONGESTIVE ( 3 patients )
LIVER DISORDER ( 3 patients )
CRYOGLOBULINAEMIA ( 2 patients )
VIRAEMIA ( 2 patients )
NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT STAGE IV ( 2 patients )
PROPHYLAXIS ( 2 patients )
RENAL CELL CARCINOMA ( 2 patients )
SMALL INTESTINE CARCINOMA ( 2 patients )
LYMPHOMA ( 2 patients )
NON-HODGKIN'S LYMPHOMA STAGE III ( 2 patients )
OFF LABEL USE ( 2 patients )
MALIGNANT MELANOMA STAGE IV ( 2 patients )
ARTHRITIS ( 2 patients )
HEPATITIS POST TRANSFUSION ( 2 patients )
NEOPLASM MALIGNANT ( 2 patients )
HEPATITIS C VIRUS TEST POSITIVE ( 1 patients )
MALIGNANT MELANOMA STAGE III ( 1 patients )
VIRAL LOAD ( 1 patients )
HEPATITIS CHRONIC ACTIVE ( 1 patients )
PATERNAL DRUGS AFFECTING FOETUS ( 1 patients )
MANTLE CELL LYMPHOMA ( 1 patients )
HEPATITIS INFECTIOUS ( 1 patients )
ESSENTIAL THROMBOCYTHAEMIA ( 1 patients )
GLIOMA ( 1 patients )
MYCOSIS FUNGOIDES ( 1 patients )
CARCINOMA ( 1 patients )
NEOPLASM ( 1 patients )
LIVER FUNCTION TEST ( 1 patients )
VASCULITIS ( 1 patients )
CRYOGLOBULINS ( 1 patients )
MALIGNANT MELANOMA STAGE II ( 1 patients )
VIRAL INFECTION ( 1 patients )
HEPATITIS CHOLESTATIC ( 1 patients )
ANTIRETROVIRAL THERAPY ( 1 patients )
EOSINOPHILIA ( 1 patients )
MATERNAL EXPOSURE DURING PREGNANCY ( 1 patients )
POST PROCEDURAL COMPLICATION ( 1 patients )
FIBROSIS ( 1 patients )
METASTATIC NEOPLASM ( 1 patients )
BIOPSY LIVER ( 1 patients )
LIVER TRANSPLANT ( 1 patients )
THROMBOSIS PROPHYLAXIS ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with ACANTHOLYSIS:

AMBIEN (10 patients)
ABRAXANE (9 patients)
ACIPHEX (9 patients)
AMPICILLIN (9 patients)
ASPIRIN (9 patients)
ATIVAN (9 patients)
AVASTIN (9 patients)
CYMBALTA (9 patients)
LEVOTHYROXINE SODIUM (9 patients)
NORCO (9 patients)
RADIATION (9 patients)
VICODIN (9 patients)
XELODA (9 patients)
ZOLOFT (9 patients)
ZOMETA (9 patients)
ZOFRAN (8 patients)
ARANESP (7 patients)
CAPECITABINE (7 patients)
CEFTRIAXONE (7 patients)
CEPHALEXIN (7 patients)
CIPROFLOXACIN (7 patients)
COLACE (7 patients)
DILAUDID (7 patients)
DOXIL (7 patients)
FEMARA (7 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (7 patients)
KEFLEX (7 patients)
LASIX (7 patients)
LORAZEPAM (7 patients)
NAPROSYN (7 patients)
NEULASTA (7 patients)
NIACIN (7 patients)
PERCOCET (7 patients)
PROVIGIL (7 patients)
RITALIN (7 patients)
SYNTHROID (7 patients)
TAXOTERE (7 patients)
VANCOMYCIN (7 patients)
VANCOMYCIN HCL (7 patients)
DEXAMETHASONE (6 patients)
FENTANYL (6 patients)
CYCLOSPORINE (4 patients)
PLAVIX (4 patients)
RELAFEN (4 patients)
ACETYLSALICYLIC ACID SRT (3 patients)
ACYCLOVIR (3 patients)
AMITIZA (3 patients)
NABUMETONE (3 patients)
NEXIUM (3 patients)
NIFEDIPINE (3 patients)
XIFAXAN (3 patients)
ALDACTAZIDE (2 patients)
AMLOR (2 patients)
AZATHIOPRINE (2 patients)
CLINDAMYCIN (2 patients)
COZAAR (2 patients)
DEPAKENE (2 patients)
DEPAS (2 patients)
DIGOXIN (2 patients)
DIPYRIDAMOL (2 patients)
EMPYNASE (2 patients)
ENALAPRIL MALEATE (2 patients)
ETRETINATE (2 patients)
FRACTAL (2 patients)
FUCIDIN CREAM (2 patients)
FUROSEMIDE (2 patients)
GAMUNEX (2 patients)
GLUCOR (2 patients)
HALCION (2 patients)
ISOSORBIDE MONONITRATE (2 patients)
LAMICTAL (2 patients)
LAXOBERON (2 patients)
LEVEMIR (2 patients)
MAGLAX (2 patients)
METHYLPREDNISOLONE (2 patients)
MINOCYCLIN (2 patients)
MOPRAL (2 patients)
MORPHINE (2 patients)
NITROGLYCERIN (2 patients)
PREDNISOLONE (2 patients)
PREDNISONE (2 patients)
SECTRAL (2 patients)
STILNOX (2 patients)
THEOPHYLLINE (2 patients)
TOPICAL ANTISEPTICS (2 patients)
ACENOCOUMAROL (1 patients)
ACENOCOUMAROL (ACENOCOUMAROL) (1 patients)
ACTIFED (1 patients)
AMILORIDE (1 patients)
AMILORIDE (AMILORIDE HYDROCHLORIDE) (1 patients)
ARNESP (1 patients)
ATENOLOL (1 patients)
ATORVASTATIN CALCIUM (1 patients)
BEMYLID (1 patients)
BETAMETHASONE DIPROPIIONATE (1 patients)
BETAMETHASONE DIPROPIONATE (1 patients)
CARBAMAZEPINE (1 patients)
CEFIXIME (1 patients)
CILAZAPRIL (1 patients)
CIPROFLOXACIN HCL (1 patients)
CIPROFLOXACIN IV (1 patients)
CISPLATIN (1 patients)
COPEGUS (1 patients)
DEXAMETHASONE ACETATE (1 patients)
DOXIUM (CALCIUM DOBESILATE) (1 patients)
ETHYOL (1 patients)
ETOPOSIDE (1 patients)
FENTANYL-100 (1 patients)
FILGRASTIM (FILGRASTIM) (1 patients)
FINASTERIDE (1 patients)
GEMZAR (1 patients)
GLIBENCLAMIDE (1 patients)
GLIMEPIRIDE (1 patients)
HEMERAN GEL (HEPARINOID) (1 patients)
HUMAN INSULIN (1 patients)
INSULIN ACTRAPID HUMAN (1 patients)
INTRON A (1 patients)
IRINOTECAN HCL (1 patients)
L-THYROXIN (1 patients)
LACIDIPINE (1 patients)
LACIDIPINE (LACIDIPINE) (1 patients)
MAGNESIUM OXIDE (MAGNESIUM OXIDE) (1 patients)
METHOTREXATE (1 patients)
MS CONTIN (1 patients)
OXYCODONE HCL (1 patients)
PEG-INTRON (1 patients)
PHENYTOIN (1 patients)
PRAVASTATIN (1 patients)
PRAVASTATIN SODIUM (1 patients)
PREDNISONE TAB (1 patients)
RADIATION THERAPY (1 patients)
REBETOL (1 patients)
RIBAVIRIN (1 patients)
TAREG (1 patients)
TOPICAL MEDICATIONS (FOR PSORIASIS) (1 patients)
ZETIA (1 patients)
Most common side effects for patients taking PEG-INTRON:
ANAEMIA (1671 patients)
NAUSEA (1404 patients)
FATIGUE (1286 patients)
WEIGHT DECREASED (1194 patients)
VOMITING (1169 patients)
DEHYDRATION (1164 patients)
WHITE BLOOD CELL COUNT DECREASED (1003 patients)
DEPRESSION (991 patients)
ASTHENIA (990 patients)
PYREXIA (912 patients)
HAEMOGLOBIN DECREASED (827 patients)
PLATELET COUNT DECREASED (809 patients)
DIZZINESS (764 patients)
DIARRHOEA (755 patients)
HEADACHE (748 patients)
DYSPNOEA (724 patients)
INSOMNIA (697 patients)
MALAISE (696 patients)
RASH (689 patients)
DECREASED APPETITE (686 patients)
PAIN (571 patients)
LOSS OF CONSCIOUSNESS (491 patients)
INFLUENZA LIKE ILLNESS (465 patients)
ANXIETY (451 patients)
NEUTROPHIL COUNT DECREASED (444 patients)
PNEUMONIA (439 patients)
CONDITION AGGRAVATED (437 patients)
ANOREXIA (426 patients)
CHEST PAIN (425 patients)
FALL (425 patients)
ARTHRALGIA (414 patients)
ALOPECIA (401 patients)
PRURITUS (384 patients)
CONFUSIONAL STATE (367 patients)
FEELING ABNORMAL (337 patients)
MEMORY IMPAIRMENT (331 patients)
CHILLS (328 patients)
RED BLOOD CELL COUNT DECREASED (321 patients)
BACK PAIN (312 patients)
DYSGEUSIA (305 patients)
MYALGIA (301 patients)
ERYTHEMA (285 patients)
SUICIDAL IDEATION (278 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (267 patients)
ABDOMINAL PAIN UPPER (265 patients)
INJECTION SITE ERYTHEMA (265 patients)
ALANINE AMINOTRANSFERASE INCREASED (264 patients)
PAIN IN EXTREMITY (252 patients)
ABDOMINAL PAIN (248 patients)
OEDEMA PERIPHERAL (247 patients)
HYPERHIDROSIS (244 patients)
TREMOR (244 patients)
HYPERURICAEMIA (243 patients)
HYPOAESTHESIA (238 patients)
DRY MOUTH (230 patients)
DRUG INEFFECTIVE (229 patients)
CONVULSION (226 patients)
NEUTROPENIA (222 patients)
COUGH (222 patients)
MUSCLE SPASMS (219 patients)
IRRITABILITY (217 patients)
ANGER (217 patients)
HYPERTENSION (217 patients)
RENAL IMPAIRMENT (215 patients)
THROMBOCYTOPENIA (213 patients)
VISION BLURRED (209 patients)
AMNESIA (208 patients)
HYPOTENSION (208 patients)
PANCYTOPENIA (204 patients)
BLOOD POTASSIUM DECREASED (199 patients)
EPISTAXIS (196 patients)
RENAL FAILURE (194 patients)
ASCITES (190 patients)
ORAL INTAKE REDUCED (187 patients)
GAIT DISTURBANCE (184 patients)
DRY SKIN (183 patients)
RENAL DISORDER (181 patients)
SOMNOLENCE (177 patients)
SYNCOPE (176 patients)
SEPSIS (175 patients)
CONSTIPATION (173 patients)
HAEMATEMESIS (170 patients)
BLOOD PRESSURE INCREASED (164 patients)
BLOOD CREATININE INCREASED (164 patients)
BLOOD GLUCOSE INCREASED (160 patients)
DRUG ERUPTION (159 patients)
HEPATIC FAILURE (157 patients)
BLOOD BILIRUBIN INCREASED (156 patients)
AGGRESSION (156 patients)
DISTURBANCE IN ATTENTION (144 patients)
PALPITATIONS (142 patients)
STAPHYLOCOCCAL INFECTION (141 patients)
LEUKOPENIA (141 patients)
ABDOMINAL DISTENSION (139 patients)
BRONCHITIS (138 patients)
RECTAL HAEMORRHAGE (135 patients)
CRYING (132 patients)
INFLUENZA (132 patients)
HAEMATOCRIT DECREASED (130 patients)
HEPATIC CIRRHOSIS (130 patients)
BLOOD PRESSURE DECREASED (129 patients)
RENAL FAILURE ACUTE (129 patients)
HYPOTHYROIDISM (129 patients)
HEART RATE INCREASED (128 patients)
DYSPHAGIA (127 patients)
CONTUSION (124 patients)
CEREBROVASCULAR ACCIDENT (123 patients)
CELLULITIS (123 patients)
DIABETES MELLITUS (122 patients)
MIGRAINE (121 patients)
INFECTION (121 patients)
URINARY TRACT INFECTION (120 patients)
BALANCE DISORDER (120 patients)
DEATH (120 patients)
JAUNDICE (120 patients)
PULMONARY EMBOLISM (119 patients)
STOMATITIS (118 patients)
DRUG EXPOSURE DURING PREGNANCY (117 patients)
BLOOD URIC ACID INCREASED (116 patients)
PANCREATITIS (115 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (112 patients)
PHARYNGOLARYNGEAL PAIN (110 patients)
TREATMENT NONCOMPLIANCE (109 patients)
PARAESTHESIA (106 patients)
CHOLELITHIASIS (105 patients)
AGITATION (104 patients)
HALLUCINATION (104 patients)
NO THERAPEUTIC RESPONSE (103 patients)
THROMBOSIS (103 patients)
MENTAL DISORDER (103 patients)
INTERSTITIAL LUNG DISEASE (103 patients)
HAEMORRHAGE (103 patients)
WEIGHT INCREASED (102 patients)
PULMONARY OEDEMA (102 patients)
HYPOKALAEMIA (102 patients)
VISUAL ACUITY REDUCED (101 patients)
BONE PAIN (101 patients)
RESPIRATORY FAILURE (100 patients)
DYSPEPSIA (100 patients)
HEPATIC ENCEPHALOPATHY (100 patients)
HYPONATRAEMIA (99 patients)
HAEMATOCHEZIA (99 patients)
DISEASE RECURRENCE (99 patients)
PLEURAL EFFUSION (98 patients)
ASTHMA (98 patients)
DELIRIUM (98 patients)
NERVOUSNESS (96 patients)
ABASIA (95 patients)
PARANOIA (95 patients)
RASH GENERALISED (95 patients)
DISORIENTATION (95 patients)
HYPOPHAGIA (95 patients)
BLISTER (94 patients)
BLOOD SODIUM DECREASED (94 patients)
HEPATITIS C (94 patients)
LIVER DISORDER (94 patients)
MYOCARDIAL INFARCTION (94 patients)
NASOPHARYNGITIS (94 patients)
CHEST DISCOMFORT (94 patients)
DRUG DOSE OMISSION (94 patients)
ACUTE RESPIRATORY DISTRESS SYNDROME (93 patients)
TACHYCARDIA (91 patients)
MOOD SWINGS (90 patients)
THIRST (90 patients)
RASH PRURITIC (89 patients)
THYROID DISORDER (89 patients)
DYSPNOEA EXERTIONAL (89 patients)
DRUG HYPERSENSITIVITY (88 patients)
HEPATIC FUNCTION ABNORMAL (88 patients)
INJECTION SITE RASH (88 patients)
LYMPHADENOPATHY (88 patients)
DYSURIA (87 patients)
SPEECH DISORDER (87 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (86 patients)
MULTI-ORGAN FAILURE (86 patients)
HEPATIC NEOPLASM MALIGNANT (86 patients)
HEAD INJURY (85 patients)
DYSARTHRIA (85 patients)
CEREBRAL HAEMORRHAGE (84 patients)
ERYTHEMA MULTIFORME (84 patients)
SUICIDE ATTEMPT (84 patients)
CARDIAC FAILURE (83 patients)
HAEMOPTYSIS (83 patients)
STRESS (83 patients)
SINUSITIS (82 patients)
AMMONIA INCREASED (82 patients)
MUSCULAR WEAKNESS (82 patients)
ROAD TRAFFIC ACCIDENT (81 patients)
VISUAL DISTURBANCE (81 patients)
ABNORMAL BEHAVIOUR (80 patients)
EYE PAIN (79 patients)
GASTROOESOPHAGEAL REFLUX DISEASE (79 patients)
PALLOR (79 patients)
CARDIAC DISORDER (78 patients)
HYPERSOMNIA (78 patients)
ATRIAL FIBRILLATION (77 patients)
INJECTION SITE PAIN (77 patients)
SKIN DISORDER (76 patients)
PRODUCTIVE COUGH (76 patients)
ENCEPHALOPATHY (75 patients)
THINKING ABNORMAL (75 patients)
SLEEP DISORDER (75 patients)
RETINOPATHY (75 patients)
INJECTION SITE REACTION (75 patients)
CEREBRAL INFARCTION (74 patients)
PANIC ATTACK (74 patients)
TINNITUS (74 patients)
FEELING COLD (73 patients)
OVERDOSE (73 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (73 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for PEG-INTRON


Issue Description / Topic Timestamp
QUESTION
ALOPECIA
Is alopecia induced by peg-Intron reversible? 2015-03-06 07:18:06
QUESTION
TOOTH LOSS
Is tooth loss a side effect of long term usage of polyethylene glycol also known AS PEG 3350? 2015-03-11 05:03:32
QUESTION
WEIGHT DECREASED
I just want to say I am just very new to weblog and definitely loved you2;8&17#re web page. Most likely I’m likely to bookmark your blog post . You really come with impressive article content. Thanks a bunch for sharing your website. 2017-03-20 09:00:19

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ACANTHOLYSIS and PEG-INTRON, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking PEG-INTRON, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in PEG-INTRON. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for PEG-INTRON experts. If you are a healthcare provider experienced in prescribing PEG-INTRON, please register here.

Your online appointment book for Blaine Rentals & Services



© 2014 FactMed, Inc
Privacy Policy
Terms of Use